Related Experiment Video

Updated: Oct 19, 2026

In Vitro and In Vivo Evaluation of Photocontrolled Biologically Active Compounds - Potential Drug Candidates for Cancer Photopharmacology
13:17

In Vitro and In Vivo Evaluation of Photocontrolled Biologically Active Compounds - Potential Drug Candidates for Cancer Photopharmacology

Published on: September 29, 2023

A novel podophyllotoxin-derived compound GL331 is more potent than its congener VP-16 in killing refractory cancer

T S Huang1, C C Lee, Y Chao

  • 1Cooperative Laboratory, Cancer Research Division, National Health Research Institutes, Taipei, Taiwan, Republic of China. tshuang@nhri.org.tw

Pharmaceutical Research
|August 18, 1999
PubMed
Abstract

Insights

GL331, a novel VP-16 homolog, demonstrates superior anti-cancer efficacy by effectively inducing apoptosis in various cancer cell lines, including drug-resistant types. This suggests GL331

Area of Science:

  • Pharmacology and Toxicology
  • Cancer Biology and Therapeutics

Background:

  • VP-16 is a standard chemotherapy agent, but its efficacy can be limited by drug resistance.
  • GL331 is a newly developed homolog of VP-16 with potential for enhanced anti-cancer activity.

Purpose of the Study:

  • To evaluate the cytotoxicity and apoptosis-inducing activity of GL331 in various human cancer cell lines.
  • To compare the efficacy of GL331 against VP-16, particularly in cancers not typically treated with VP-16.
  • To investigate GL331's activity in multidrug resistance (MDR)-1 overexpressing cell lines.

Main Methods:

  • Cytotoxicity was assessed using MTT and clonogenic survival assays across multiple cancer cell lines (nasopharyngeal, hepatocellular, gastric, colon, cervical, neuroblastoma).
  • Western blot analysis was employed to determine MDR-1 expression levels.
  • Apoptosis induction was evaluated through Annexin V-staining flow cytometry and DNA ladder assays.

Main Results:

  • GL331 exhibited significantly greater efficacy than VP-16 in reducing cancer cell viability, with 2.5 to 17-fold lower ID50 values.
  • GL331 demonstrated potent cell-killing activity even in MDR-1 overexpressing cell lines (e.g., HCC36, SW620).
  • The enhanced cytotoxicity of GL331 is attributed to its superior ability to induce apoptotic cell death.

Conclusions:

  • GL331 possesses superior anti-cancer activity compared to VP-16, characterized by enhanced cancer cell killing and apoptosis induction.
  • GL331 demonstrates efficacy against drug-resistant cancer cells, suggesting a potential advantage in overcoming multidrug resistance.
  • The findings support GL331's potential as a superior therapeutic agent in clinical cancer treatment.

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...